their optimum working dilutions by titration
assay.
References:
1. Chorvath, B., et al., Neoplasma, 34, 685 (1987).
2. Chorvath, B., et al., in Leukocyte Typing IV,
Knapp, W. (ed.), p.
0.25, 0.5, 1ml
100 ml
100 ml
A 5324
T 0565
B 6404
References
1. Laemmli, U.K., Nature, 227, 680-685 (1970).
2. Towbin, H., et al., Proc. Natl. Acad. Sci. USA, 76,
T 0565
B 6404
References
1. Laemmli, U.K., Nature, 227, 680-685 (1970).
2. Towbin, H., et al., Proc. Natl. Acad. Sci. USA, 76,
4350-4354 (1979).
ECL and ECL Plus are
of cells under study
and the sensitivity of the instrument used.
References
1. Chorvath, B., et al., Neoplasma, 34, 685 (1987).
2. Chorvath, B., et al., in Leukocyte Typing IV, Knapp,
W. (ed.), p
determine their optimum working
dilutions by titration assay.
References
1. Chorvath, B., et al., Neoplasma, 34, 685 (1987).
2. Chorvath, B., et al., in Leukocyte Typing IV, Knapp,
W. (ed.)
percentage
positive using saturating monoclonal antibody levels.
References
1. Chorvath, B., et al., Neoplasma, 34, 685 (1987).
2. Chorvath, B., et al., in Leukocyte Typing IV,
Knapp, W. (ed.)
leucocyte gates by inappropriate
subpopulation(s).
References
Chorvath, B., et al., Neoplasma, 34, 685 (1987).
Chorvath, B., et al., In: Leukocyte Typing IV, Knapp, W.
(Ed.), p. 634, Oxford University
long enough. Reassemble blotting apparatus and continue
transfer.
References
1. Laemmli, U.K., Nature, 227, 680-685 (1970).
ProteoQwest, ColorBurst, and SigmaMarker are
trademarks of Sigma-Aldrich
Immunology 49, 685.
NEW! Calpain Inhibitors
Calpain Inhibitor X [Z-L-Abu-CONH-ethyl]
A cell-permeable dipeptidyl α-ketoamide that acts as a potent, reversible, active site inhibitor of
calpains-1 and -2 (Ki
3840 KPNA4 M NP_002259.1 y y y
722 Transportin 1 T0825 3842 TNPO1 M NP_002261.3 y y y
203 Cytokeratin peptide 4 C5176 3851 KRT4 M NP_002263.2 y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3
3840 KPNA4 M NP_002259.1 y y y
722 Transportin 1 T0825 3842 TNPO1 M NP_002261.3 y y y
203 Cytokeratin peptide 4 C5176 3851 KRT4 M NP_002263.2 y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3
3840 KPNA4 M NP_002259.1 y y y
722 Transportin 1 T0825 3842 TNPO1 M NP_002261.3 y y y
203 Cytokeratin peptide 4 C5176 3851 KRT4 M NP_002263.2 y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3
n/d
685 Sp1 S9809 P y n/d n/d
686 Spred-2 S7320 P y y y
687 Striatin S0696 P n/d y y
688 Substance P Receptor S8305 P y y y
689 SMAC/Diablo S0941 P y y n/d
690 SUMO-1 S8070 P y n/d n/d
691 SUMO-1